Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this research is to see how certain genetic variations relate to side effects and outcomes experienced while receiving treatment with azacitidine and venetoclax.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzona diagnoza białaczki ostrej
- •Planowane pierwszsze leczenie azacytydyną i venetoklaksem
- •Umiejętność czytania i rozumienia języka angielskiego lub hiszpańskiego
- •Zdolność do uczestnictwa w badaniu zgodnie z instrukcjami zespołu badawczego
- •Podpisana świadoma zgoda na uczestnictwo
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 24, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
Levine Cancer Institute
Charlotte, United States
Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, United States
Trial contact
Courtney Schepel
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/26/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.